Impact BioMedical (IBO) Q3 2025 earnings summary

Executive summary

• Focused on developing and commercializing proprietary healthcare and wellness technologies, with a portfolio including Linebacker, Laetose, 3F, and Equivir, and ongoing evaluation of new technologies.

• Operations are conducted through several subsidiaries, with majority or full ownership in each.

• Completed acquisition of Celios air purification technology in Q1 2025 and listed on NYSE American in September 2024.

Financial highlights

• Reported revenue of $18,000 for the three months and $25,000 for the nine months ended September 30, 2025, from Celios air purification sales.

• Net loss of $1,475,000 for the quarter and $17,105,000 for the nine months, compared to net income of $4,241,000 and $2,363,000 in the prior year periods.

• Operating loss for the nine months was $3,112,000, up from $2,522,000 year-over-year.

• Total assets decreased to $18,208,000 as of September 30, 2025, from $20,290,000 at year-end 2024.

• Cash and cash equivalents dropped to $12,000 from $1,999,000 at year-end.

Outlook and guidance

• Management plans to monetize intellectual property and control costs to address going concern risks.

• Anticipates closing a merger and share exchange with Dr Ashleys Limited in Q1 2026.